plamotamab + tafasitamab + lenalidomide

plamotamab + tafasitamab + lenalidomide is a **combination therapy** under investigation for the treatment of **relapsed or refractory diffuse large B-cell lymphoma (DLBCL)** in adults ineligible for autologous stem-cell transplant. - **plamotamab** is a bispecific monoclonal antibody targeting both CD3 on T-cells and CD20 on B-cells, designed to recruit T-cell cytotoxicity against CD20+ B-cells[4]. - **tafasitamab** is a humanized monoclonal antibody targeting CD19, engineered to improve Fc-mediated effector functions and induce direct and immune-mediated B-cell cytotoxicity through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and phagocytosis[4]. - **lenalidomide** is an immunomodulatory small molecule that enhances T-cell and natural killer (NK) cell function, and directly disrupts tumor-promoting pathways[2][4]. The rationale for combining plamotamab with tafasitamab and lenalidomide is to leverage **complementary mechanisms**: plamotamab enables T-cell recruitment for cytotoxicity against CD20+ cells, tafasitamab mediates B-cell lysis via multiple immune mechanisms, and lenalidomide enhances antitumor immunity. The triple therapy aims to overcome resistance associated with antigen loss (CD19 or CD20) and improve overall efficacy in heavily pre-treated DLBCL patients[4]. This combination is currently in phase 2 clinical evaluation (XmAb13676-03 trial) in adults with relapsed/refractory DLBCL, comparing the triple regimen versus tafasitamab + lenalidomide doublet[4].

Other names

XmAb13676-03XmAb-13676-03XmAb 13676-03